New approaches in the treatment of hepatitis C

doi:10.3748/wjg.v22.i4.1421

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (22053)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

1689

WORD

453

HTML

14123

Tables (1-4)

456

Sum=16721

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

552

Download

1144

Sum=1696

Publishing Process of This Article

Item

Count

Browse

1418

Download

2220

Sum=3638

Jan 28, 2016 (publication date) through Nov 28, 2025

Times Cited of This Article

Times Cited (119)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Topic Highlight

World J Gastroenterol. Jan 28, 2016; 22(4): 1421-1432
Published online Jan 28, 2016. doi: 10.3748/wjg.v22.i4.1421

Table 1 Recommendations for therapy in patients with genotype 1a

Patient characterization	Recommended	Duration (wk)	Scientific evidence	Real-world evidence
Genotype 1a naive noncirrhotic	SOF + LDV	12	ION-1
	SOF + LDV (CV < 6 × 10⁶ UI/mL)	8	ION-3
	OBV + PTVR + DSV + RBV	12	SAPHIRE I PEARL
	SOF + SIM	12	COSMOS	TARGET TRIO
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1anaive cirrhotic	SOF + LDV	12	ION-1
	OBV + PTVR + DSV + RBV	12	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1a retretated noncirrhotic	SOF + LDV	12	ION-2
	OBV + PTVR + DSV + RBV	12	SAPHIRE-II
	SOF + SIM	12	COSMOS
	SOF + DCV	12/24
Genotipo 1a retreated cirrhotic	SOF + LDV + RBV	12	ION-2
	SOF + LDV	24	ION-2
	OBV + PTVR + DSV + RBV	12/24	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DVC	24

SOF: Sofosbuvir; LDV: Ledipasvir.

Full Size Table

Table 2 Recommendations for therapy in patients with genotype 1b

Patient characterization	Recommended	Duration	Scientific evidence	Real-world evidence
Genotype 1b naive noncirrhotic	SOF + LDV	12	ION-1
	SOF + LDV (CV < 6 × 10⁶ UI/mL)	8	ION-3
	OBV + PTVR + DSV	12	SAPHIRE I PEARL
	SOF + SIM	12	COSMOS	TARGET TRIO
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1b naive cirrhotic	SOF + LDV	12	ION-1
	OBV + PTVR + DSV + RBV	12	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DCV	12
	SOF + PEG + RBV	12	NEUTRINO
Genotype 1b retreated noncirrhotic	SOF + LDV	12	ION-2
	OBV + PTVR + DSV	12	SAPHIRE-II
	SOF + SIM	12	COSMOS
	SOF + DCV	12/24
Genotype 1b retreated cirrhotic	SOF + LDV + RBV	12	ION-2
	SOF + LDV	24	ION-2
	OBV + PTVR + DSV + RBV	12	TURQUOISE-II PEARL
	SOF + SIM	12	COSMOS
	SOF + DVC	24

SOF: Sofosbuvir; LDV: Ledipasvir.

Full Size Table

Table 3 Recommedation for therapy in patients with genotypes 2 and 3

Patient characterization	Recommended	Duration (wk)	Scientific evidence
Genotype 2 naive noncirrhotic/cirrhotic	SOF + RBV	12	Fission positron
Genotype 2 naive noncirrhotic/cirrhotic	SOF + PEG + RBV	12	Lonestar-2
Genotype 2 retretated noncirrhotic	SOF + RBV	12	Fussion valence
Genotype 2 retretated noncirrhotic	SOF + PEG + RBV	12	Lonestar-2
Genotype 2 retreated cirrhotic	SOF + PEG + RBV	12	Lonestar-2
Genotype 2 retreated cirrhotic	SOF + RBV	16	Fussion valence
Genotype 3 naive and retreated noncirrhotic/cirrhotic	SOF + RBV	24	Valence
	SOF + PEG + RBV	12	Lonestar-2
	SOF + LDV + RBV	12	Electron-2
	SOF + DVC (No en cirróticos)	12	Ally-3

Full Size Table

Table 4 Recommendations for therapy in patients with genotypes 4, 5 and 6

Patient characterization	Recommended	Duration (wk)	Scientific evidence
Genotype 4	SOF + PEG + RBV	12	Atomic neurino
	SOF + LDV	12	Synergy
	SOF + RBV	12	Egyptian
		24
		(cirrhotics and nulls responders)
	OBV + PTV + RBV (noncirrhotics)	12	Pearl-1
Genotype 5	SOF + PEG + RBV	12	Neutrino
Genotype 6	SOF + PEG + RBV	12	Atomic
Genotype 6	SOF + LDV	16	Electron-2

Full Size Table

Citation: González-Grande R, Jiménez-Pérez M, González Arjona C, Mostazo Torres J. New approaches in the treatment of hepatitis C. World J Gastroenterol 2016; 22(4): 1421-1432
URL: https://www.wjgnet.com/1007-9327/full/v22/i4/1421.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i4.1421